Tine Jess

Tine Jess

Auto-generated profile, based on publicly available information

Tine Jess

Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
TJTine Jess
Tine Jess
CRChristine Rungoe
Christine Rungoe
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet

22 June 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
TBTania H. Bisgaard
Tania H. Bisgaard
KAKristine H. Allin
Kristine H. Allin
LKLaurie Keefer
Laurie Keefer
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan
TJTine Jess
Tine Jess

1 August 2012 in Gastroenterology
Verified
Journal Article
Closed access
TJTine Jess
Tine Jess
JSJacob Simonsen
Jacob Simonsen
KJKristian Tore Jørgensen
Kristian Tore Jørgensen
BPBo Vestergaard Pedersen
Bo Vestergaard Pedersen
NNNete Munk Nielsen
Nete Munk Nielsen
MFMorten Frisch
Morten Frisch

17 March 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
MAManasi Agrawal
Manasi Agrawal
KAKristine H. Allin
Kristine H. Allin
FPFrancesca Petralia
Francesca Petralia
JCJean-Frederic Colombel
Jean-Frederic Colombel
TJTine Jess
Tine Jess

9 January 2023 in Gut
Verified
Journal Article
Open access
PDF file
AFAdam Faye
Adam Faye
KAKristine Højgaard Allin
Kristine Højgaard Allin
AIAske T Iversen
Aske T Iversen
MAManasi Agrawal
Manasi Agrawal
JFJeremiah Faith
Jeremiah Faith
TJTine Jess
Tine Jess
Background There is an increasing incidence of inflammatory bowel disease (IBD) for which environmental factors are suspected. Antibiotics have been associated with development of IBD in earlier generations, but their influence on IBD risk in adults is uncertain. Objective To assess the impact of antibiotic exposure, including dose–response, timing and antibiotic class, on the risk of IBD in all individuals aged ≥10 years. Design Using Denmark nationwide registries, a population-based cohort of residents aged ≥10 years was established between 2000 and 2018. Incidence rate ratios (IRRs) for IBD following antibiotic exposure were calculated using Poisson regression. Results There were a total of 6 104 245 individuals, resulting in 87 112 328 person-years of follow-up, and 52 898 new cases of IBD. Antibiotic exposure was associated with an increased risk of IBD as compared with no antibiotic exposure for all age groups, although was greatest among individuals aged 40–60 years and ≥60 years (age 10–40 years, IRR 1.28, 95% CI 1.25 to 1.32; age 40–60 years, IRR 1.48, 95% CI 1.43 to 1.54; age ≥60 years, IRR 1.47, 95% CI 1.42 to 1.53). For all age groups a positive dose–response was observed, with similar results seen for both ulcerative colitis and Crohn’s disease. The highest risk of developing IBD was seen 1–2 years after antibiotic exposure, and after use of antibiotic classes often prescribed to treat gastrointestinal pathogens. Conclusion Antibiotic exposure is associated with an increased risk of IBD, and was highest among individuals aged 40 years and older. This risk increased with cumulative antibiotic exposure, with antibiotics targeting gastrointestinal pathogens and within 1–2 years after antibiotic exposure.

1 January 2013 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
TJTine Jess
Tine Jess
MFMorten Frisch
Morten Frisch
JSJacob Simonsen
Jacob Simonsen